Who are DMB-3115's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): ODM-203 (Period 1), PP1M, JNJ-77242113, E3810, LY2062430.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/dmb-3115.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-15 · How we verify

DMB-3115 — Competitive Intelligence Brief

DMB-3115 (DMB-3115) competitive landscape: 5 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: PDE10A inhibitor. Area: Neurology/Psychiatry.

phase 3 PDE10A inhibitor PDE10A Neurology/Psychiatry Small molecule Live · refreshed every 30 min

Target snapshot

DMB-3115 (DMB-3115) — Dong-A ST Co., Ltd.. DMB-3115 is a selective inhibitor of phosphodiesterase 10A (PDE10A) that increases intracellular cyclic nucleotide levels in the brain.

Comparator set (5 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
DMB-3115 TARGET	DMB-3115	Dong-A ST Co., Ltd.	phase 3	PDE10A inhibitor	PDE10A
ODM-203 (Period 1)	ODM-203 (Period 1)	Orion Corporation, Orion Pharma	marketed	PDE10A inhibitor	PDE10A (phosphodiesterase 10A)
PP1M	PP1M	Janssen Research & Development, LLC	phase 3	PDE10 inhibitor	PDE10A
JNJ-77242113	JNJ-77242113	Janssen Research & Development, LLC	phase 3	Phosphodiesterase 10A (PDE10A) inhibitor	PDE10A
E3810	E3810	Eisai Co., Ltd.	phase 3	PDE10A inhibitor	PDE10A (Phosphodiesterase 10A)
LY2062430	LY2062430	Eli Lilly and Company	phase 3	PDE10A inhibitor	PDE10A (Phosphodiesterase 10A)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (PDE10A inhibitor class)

Dong-A ST Co., Ltd. · 1 drug in this class
Eisai Co., Ltd. · 1 drug in this class
Eli Lilly and Company · 1 drug in this class
Orion Corporation, Orion Pharma · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). DMB-3115 — Competitive Intelligence Brief. https://druglandscape.com/ci/dmb-3115. Accessed 2026-05-15.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab